Melanotan 2 Research: Mechanism, Pigmentation, and Key Studies
Start here
Melanotan 2 works by imitating a natural hormone that tells skin cells to make pigment. When it docks onto a receptor called MC1R on a pigment cell, it sets off a chain of chemical signals inside the cell that ends in more dark pigment being made — the same machinery a tan uses, but switched on without sunlight. The same compound also reaches receptors in the brain (MC4R), which is how it dulls appetite and triggers erections.
The formal evidence is small. A pilot study in three men showed skin darkening; a slightly larger study showed erections in men with erectile dysfunction; the rest of the work is mostly in rats and mice. This page walks through the mechanism in plain terms, then the actual studies, then the part this site cares about most — what melanocyte stimulation does to moles. No doses here are advice.
Melanotan and MT2: what the names mean
A note on naming, because the search terms vary. Melanotan is the informal family name; MT2 and Melanotan II are the same compound this site covers. Melanotan I (afamelanotide) is a different, more selective linear analog. Melanotan 2 itself is a cyclic, lactam-bridged heptapeptide — sequence Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2, molecular formula C50H69N15O9, molecular weight about 1,024 Da, CAS 121062-08-6. The cyclization (a ring closed by an internal bond) makes it more potent and more resistant to breakdown than the natural hormone [34].
The melanogenesis cascade: how Melanotan 2 darkens skin
Melanotan 2 is a non-selective agonist of the melanocortin receptors MC1R through MC5R. The pigment effect runs through MC1R on melanocytes. Binding activates the enzyme adenylyl cyclase, which raises intracellular cyclic AMP (cAMP, a common cellular 'go' signal). Raised cAMP activates protein kinase A (PKA), which switches on the transcription factor CREB, which in turn raises MITF — the master regulator of the pigment-cell program. MITF drives expression of tyrosinase, the rate-limiting enzyme of melanin synthesis, shifting output toward eumelanin, the darker and more photoprotective form of the pigment [1][34]. The practical upshot is the documented one: skin and hair darken without ultraviolet light. The first solution-phase total synthesis of the peptide, reported in 2008, characterized it plainly as a cyclic heptapeptide that stimulates the skin-tanning process [36].
The pilot pigmentation study
The foundational human study is a 1996 single-blind, alternating-day, placebo-controlled pilot Phase I trial in three healthy male volunteers [1]. Subcutaneous Melanotan 2 was escalated from 0.01 to 0.025-0.03 mg/kg, dosed every other weekday for two weeks. After only five low doses, facial, upper-body, and buttock pigmentation increased in two of the three subjects — without any UV exposure. Spontaneous penile erections lasting one to five hours and mild nausea accompanied the dosing, and somnolence became dose-limiting at 0.03 mg/kg. The authors recommended 0.025 mg/kg/day for subsequent Phase I work. These figures are study-design facts from a 1996 trial, not dosing recommendations, and Melanotan 2 is not approved for human use.
Melanotan 2 tanning versus the approved analog
Melanotan 2 tanning is what drives most public interest, but it is worth separating from the one melanocortin tanning compound that did reach approval. The linear analog afamelanotide (Melanotan I) completed Phase 3 trials and is approved for erythropoietic protoporphyria (EPP), a rare disorder causing painful skin reactions to light; long-term observational data exist for that approved use [30][31]. Melanotan 2 is not that compound and shares none of its approvals. A historical review traces the full lineage — Melanotan I tested for tanning, Melanotan 2 tested for erectile dysfunction, and the further analog bremelanotide commercialized for sexual dysfunction [3].
The erectile-function and appetite findings
The sexual effect was confirmed in a double-blind, placebo-controlled crossover study of ten men with psychogenic erectile dysfunction [2]. Subcutaneous Melanotan 2 at 0.025 mg/kg produced clinically apparent erections in eight of ten men; mean duration of greater than 80% tip rigidity was 38.0 minutes with the peptide versus 3.0 minutes with placebo (p=0.0045), with transient nausea, stretching, and yawning that needed no treatment. The effect is central — driven by melanocortin signaling in the brain, not by the blood vessels of the penis.
The appetite effect is well documented preclinically. In male C57BL/6J mice, microinjecting Melanotan 2 directly into the nucleus accumbens (a brain reward region) at 0.1-1 nmol per side significantly reduced both food consumption and the motivation to work for food, without causing taste aversion or changing metabolic rate [35]. This is the MC4R-mediated appetite pathway that underlies the reduced hunger users describe.
The mole and melanoma literature
Because the compound activates pigment cells everywhere, not only where a tan is wanted, the dermatology literature has accumulated a distinctive set of reports. A 2012 case described eruptive dysplastic nevi following melanotan use, with multiple new and changing moles showing histopathologic dysplasia [4]. A British Medical Journal report linked a change in moles to an unlicensed 'sun-tan jab' [13]. Dermoscopy documented measurable darkening and change in pigmented lesions during use [10], and a single mono-dose injection was reported to produce eruptive nevi and darkening of pre-existing nevi within 24 hours in one case [5]. Most seriously, separate reports document melanoma and melanoma in situ associated with use [7][8][9]. The mechanism is consistent: stimulate melanocytes and you stimulate the cells from which both benign nevi and melanoma arise. A teenage patient with familial atypical multiple mole melanoma (FAMMM) syndrome who combined melanotan with sunbed use developed a dysplastic compound nevus that partly reversed on stopping [11] — a reminder that genetic susceptibility and concurrent UV raise the stakes. None of this establishes causation of cancer, but the volume and consistency of the case reports is the reason this site exists.